Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma
Por:
Fernandez-de-Misa, R, Hernandez-Machin, B, Combalia, A, Muret, MPG, Servitje, O, Muniesa, C, Gallardo, F, Pujol, RM, Marti, RM, Ortiz-Brugues, A, Maronas-Jimenez, L, Ortiz-Romero, PL, Rius, LB, Izu, R, Roman, C, Canueto, J, Blanes, M, Morillo, M, Bastida, J, Penate, Y, Gala, SP, Lara, PE, Gil, AP, Estrach, T
Publicada:
1 abr 2020
Ahead of Print:
1 nov 2019
Resumen:
Background Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking. Objective To identify prognostic factors for specific survival in patients with PCALCL. Methods Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed. Results One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI: 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P < 0.001). Nodal progression was an independent predictive parameter for shorter survival (P = 0.011). Conclusion Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL.
Filiaciones:
Fernandez-de-Misa, R:
Hosp Univ Nuestra Senora Candelaria, Dept Dermatol, Santa Cruz De Tenerife, Spain
Hosp Univ Nuestra Senora Candelaria, Res Unit, Santa Cruz De Tenerife, Spain
Hernandez-Machin, B:
NHS Trust Liverpool, Dept Dermatol, DMC Healthcare, Sefton Suite, Liverpool, Merseyside, England
Combalia, A:
Univ Barcelona, Hosp Clin, Dept Dermatol, Barcelona, Spain
Muret, MPG:
UAB, Dept Dermatol, Hosp Santa Creu & St Pau, Barcelona, Spain
Servitje, O:
Hosp Univ Bellvitge, Dept Dermatol, IDIBELL, Barcelona, Spain
Muniesa, C:
Hosp Univ Bellvitge, Dept Dermatol, IDIBELL, Barcelona, Spain
Gallardo, F:
Univ Autonoma Barcelona, Hosp Mar, Dept Dermatol, Barcelona, Spain
Pujol, RM:
Univ Autonoma Barcelona, Hosp Mar, Dept Dermatol, Barcelona, Spain
Marti, RM:
Hosp Arnau Vilanova, Dept Dermatol, IRBLleida, Lleida, Spain
Inst Salud Carlos III, Ctr Biomed Res Canc CIBERONC, Madrid, Spain
Ortiz-Brugues, A:
Hosp Arnau Vilanova, Dept Dermatol, IRBLleida, Lleida, Spain
Maronas-Jimenez, L:
Univ Complutense, Dept Dermatol, Hosp Univ Octubre 12, I 12 Res Inst, Madrid, Spain
Ortiz-Romero, PL:
Inst Salud Carlos III, Ctr Biomed Res Canc CIBERONC, Madrid, Spain
Univ Complutense, Dept Dermatol, Hosp Univ Octubre 12, I 12 Res Inst, Madrid, Spain
Rius, LB:
Hosp Basurto, Dept Dermatol, Bilbao, Spain
Izu, R:
Hosp Basurto, Dept Dermatol, Bilbao, Spain
Roman, C:
Hosp Univ Salamanca, Dept Dermatol, Salamanca, Spain
Canueto, J:
Hosp Univ Salamanca, Dept Dermatol, Salamanca, Spain
Blanes, M:
Hosp Gen Univ Alicante, Dept Dermatol, Alicante, Spain
Morillo, M:
Hosp Univ Virgen Rocio, Dept Dermatol, Seville, Spain
Bastida, J:
Hosp Univ Dr Negrin, Dept Dermatol, Las Palmas Gran Canaria, Spain
Penate, Y:
Complejo Hosp Univ Insular Materno Infantil, Dept Dermatol, Las Palmas De Gc, Spain
Gala, SP:
Hosp Univ Ramon & Cajal, Dept Dermatol, Madrid, Spain
Lara, PE:
Hosp Univ Infanta Cristina, Dept Dermatol, Madrid, Spain
Gil, AP:
Hosp Virgen Valme, Dept Dermatol, Seville, Spain
Estrach, T:
Univ Barcelona, Hosp Clin, Dept Dermatol, IDIBAPS, Barcelona, Spain
|